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Abstract: The present study describes palladium-catalyzed one pot Suzuki cross-coupling reaction to 
synthesize a series of novel pyridine derivatives 2a–2i, 4a–4i. In brief, Suzuki cross-coupling reaction 
of 5-bromo-2-methylpyridin-3-amine (1) directly or via N-[5-bromo-2-methylpyridine-3-yl]acetamide 
(3) with several arylboronic acids produced these novel pyridine derivatives in moderate to good 
yield. Density functional theory (DFT) studies were carried out for the pyridine derivatives 2a–2i 
and 4a–4i by using B3LYP/6-31G(d,p) basis with the help of GAUSSIAN 09 suite programme. The 
frontier molecular orbitals analysis, reactivity indices, molecular electrostatic potential and dipole 
measurements with the help of DFT methods, described the possible reaction pathways and potential 
candidates as chiral dopants for liquid crystals. The anti-thrombolytic, biofilm inhibition and haemolytic 
activities of pyridine derivatives were also investigated. In particular, the compound 4b exhibited the 
highest percentage lysis value (41.32%) against clot formation in human blood among all newly 
synthesized compounds. In addition, the compound 4f was found to be the most potent against 
Escherichia coli with an inhibition value of 91.95%. The rest of the pyridine derivatives displayed 
moderate biological activities. 
Keywords: Suzuki cross-coupling reaction; pyridine derivatives; density functional theory (DFT); 
anti-thrombolytic; biofilm inhibition; haemolysis 
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1. Introduction 
It is generally accepted that cross-coupling reactions catalyzed by transition metals offer facile 
systematic routes for carbon-carbon bond formation when synthesizing a variety of organic compounds 
of interest [1]. Among the various transition metals, palladium (Pd) exhibits the highest activity for 
C–C coupling reactions [2]. The Suzuki-Miyaura cross-coupling reaction provides an appropriate and 
practical approach for the synthesis of biaryl compounds, due to its ability to tolerate a wide range of 
functional groups and good reaction yields [3]. In the past, pyridine and its derivatives have been used 
as starting precursors for several useful compounds due to their availability and stability for direct 
cross-coupling reactions [4–12]. With this approach, Liu and co-workers have described the Suzuki 
cross-coupling reactions between 2-aryl-1,2,3-triazole-N-oxides and pyridine-N-oxide with good 
yield of the final products [5]. Pyridine compounds have a number of biological activities, including 
anti-tumor [13,14], anti-viral [15–17], anti-microbial [18,19], anti-diabetic [20] anti-leishmanial [21] 
and anti-oxidant [22]. Recently, we have reported the efficient synthesis of a series of 5-aryl-2-bromo-3-
hexylthiophene-based compounds and a thorough investigation of their biological activities [23]. The 
biological importance of heterocyclic compounds inspired us to now synthesize some pyridine 
derivatives and investigate their biological activities. In the present work, we carried out the successful 
synthesis of a series of novel pyridine derivatives by making use of Suzuki-Miyaura cross-coupling 
reactions. These novel pyridine derivatives were further explored by the computational studies using 
DFT methods and their biological activities were also examined in the course of this study. 
2. Results and Discussion 
2.1. Synthesis 
Recently, we have reported the successful synthesis of 5-aryl-2-bromo-3-hexylthiophene derivatives 
by employing the Suzuki cross-coupling reaction [23]. Ikram and co-workers have also reported the 
application of double Suzuki cross-coupling reactions for the synthesis of 2,5-biaryl-3-hexylthiophene 
derivatives [24]. In the present work we have utilized the commercially available 5-bromo-2-
methylpyridin-3-amine (1), which was coupled with a series of arylboronic acids in the presence of 
tetrakis(triphenylphosphine)palladium(0) as a catalyst and K3PO4 as a base to produce a series of 
novel 5-aryl-2-methylpyridin-3-amine molecules 2a–2i (Scheme 1, Figure 1).  
 
Scheme 1. Synthesis of compounds 2a–2i, 3 and 4a–4i; Reagents and Conditions: (i) 1 (0.2 g, 1.069 mmol), 
Pd(PPh3)4 (5 mol %), arylboronic acid (1.1759 mmol), K3PO4 (2.318 mmol), 1,4-dioxane:water (2:0.5 mL), 
18 h reflux, 90 °C; (ii) 1 (2.0 g, 12.7 mmol), acetic anhydride (1.95 g, 19.1 mmol) in acetonitrile (20 mL); (iii) 
3 (0.1 g, 1 mmol), Pd(PPh3)4 (5 mol %), arylboronic acid (1.1 mmol), K3PO4 (1.5 mmol), 1,4-dioxane:water 
(2:0.5 mL), 18 h reflux, 90 °C. 
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Figure 1. Structures of the newly synthesized pyridine derivatives viz. 2a–2i, 3, 4a–4i. 
These Suzuki cross-coupling reactions were carried out in a solvent mixture of 1,4-dioxane and 
water in the volume ratio of 4:1, respectively. As expected, the desired pyridine derivatives were 
obtained in moderate to good yields. The labile protons in compounds such as carboxylic acids, 
alcohols and primary amines make them a poor choice for Suzuki coupling reactions [25]. It has been 
reported that when an amine binds itself with a Pd center, its deprotonation occurs readily with a 
base such as K3PO4, which in turn causes a concomitant decrease in the pKa [26,27]. Therefore, instead of 
using carboxylic acids, alcohols and primary amines, we have utilized an amide such as N-[5-bromo-2-
methylpyridine-3-yl]acetamide (3) as the starting material for these Suzuki coupling reactions. This 
particular amide (N-[5-bromo-2-methylpyridine-3-yl]acetamide (3)) was synthesized by the reaction 
of 5-bromo-2-methylpyridin-3-amine (1) with acetic-anhydride following Scheme 1 (conditions ii). 
The Suzuki cross-coupling reactions of this newly synthesized compound 3 with several arylboronic 
acids in the presence of Pd(PPh3)4 and K3PO4 produced novel pyridine derivatives in moderate to good 
yields [28]. These cross-coupling reactions were carried out in a solvent mixture of 1,4-dioxane and 
water (volume ratio ~ 4:1), while the temperature was kept between 85 °C to 95 °C [29]. Interestingly, 
the N-[5-bromo-2-methylpyridine-3-yl]acetamide (3) reacted efficiently with various functional group 
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containing arylboronic acids affording the corresponding pyridine derivatives. The effect of different 
arylboronic acids was studied in the same reaction environment. The experimental results reveal that 
the electron-donating or electron-withdrawing substituents on the arylboronic acids had no prominent 
effect on either the reaction rates or the product yields. The structures of all these newly synthesized 
pyridine based compounds were confirmed by 1H-NMR and13C-NMR studies. 
2.2. Density Functional Theory (DFT) Studies 
Density functional theory (DFT) studies on all newly synthesized compounds 2a–2i and 4a–4i were 
carried out to investigate the structure properties relationships in these systems. First of all, the 
geometry optimization of both series 2a–2i and 4a–4i were simulated using the GAUSSIAN 09 software 
at B3LYP/6-31G(d,p) level of DFT. Frequency calculations at the same level proved the true optimization, 
(no imaginary frequency was observed). Structural analysis like frontier molecular orbitals analysis 
(FMOs), electrostatic potential (ESP) and dipole moment were executed with the help of optimized 
geometries. 
2.2.1. Frontier Molecular Orbital (FMO) Analysis 
At present, FMO analysis using DFT methods is becoming vital to explain the reactivity and 
molecular excitations, as well as the electronic properties of molecular systems [30]. Frontier orbitals 
(HOMO/LUMO) mainly participate in electronic transitions and their energy gap is used to explain 
the reactivity and kinetic stability [31]. A low value of HOMO-LUMO energy gap indicates high 
reactivity and less kinetic stability [32]. The opposite is true if the value of HOMO-LUMO energy gap 
is high. The FMO analysis of all compounds 2a–2i and 4a–4i was performed at the B3LYP/6-31G(d,p) 
level of theory, and the respective surfaces are shown in Figure S1 (Supplementary Materials). The 
corresponding HOMO/LUMO energy values along with energy gap (ΔE) are provided in Table 1. The 
ΔE values for compounds 2a–2i were found in the range ~4.13–4.86 eV, whereas for the compounds 4a–
4i, these values fell in the 4.51–5 eV range. The relatively high values of ΔE for the newly synthesized 
biphenyl derivatives 4a–4i indicate that these compounds are kinetically more stable than compounds 
2a–2i. Among all the newly synthesized derivatives, the compound 4b showed the value (~5.05 eV), 
which indicates its higher stability and less reactivity. In contrast, compound 2g exhibited the lowest ΔE 
value (~4.13 eV) among all the newly synthesized pyridine derivatives, indicating its poor stability 
and corresponding high reactivity. 
The dispersion of iso-density in the HOMO and LUMO orbitals of compounds 2a–2i displayed 
similar trends except for 2g. In the HOMO orbitals, the iso-density dispersion was mainly observed on 
the biphenyl skeleton, which contained the amino and methyl groups attached to the pyridine ring. 
In compounds 2a, 2c, 2d, 2e and 2f, the groups attached to the para position of phenyl ring were involved 
with the π-electron cloud on the ring, whereas the groups attached to the meta position showed no 
participation with the π-electron cloud, as observed in the case of compounds 2b, 2g, 2h and 2i. 
Similarly, in case of the LUMO orbitals, the electronic cloud dispersion in compounds 2a–2i exhibited 
similar trends except for compound 2g. The iso-density of the LUMO orbitals reveals that the amino 
group in the pyridine ring and the groups attached to the meta position in the phenyl ring showed no 
involvement with the π-electron cloud, whereas the groups attached to the para position displayed 
direct participation in the electronic transitions. The dispersion of the iso-density in the HOMO orbitals 
of compound 2g was mainly restricted around the pyridine ring, along with the groups attached to it, 
whereas it was totally shifted to the phenyl ring in the LUMO, indicating a rapid movement of 
electrons and more reactivity of compound 2g. The relatively low energy gap between the HOMO 
and LUMO orbitals of compound 2g also support this finding. 
In the second series of compounds 4a–4i, the iso-density showed a high dependence on the 
substituents attached to the biphenyl skeleton. In the HOMO orbitals of all compounds 4a–4i, except 
for 4g, the iso-density was dispersed around the main skeleton to which substituents were attached at 
the para position. In the HOMO orbitals, a shift in iso-density was observed from the amide group of 
the pyridine ring toward the pyridine and phenyl ring. Again, the iso-density dispersion in compound 
4g was different. In the HOMO orbitals of compound 4g, the dispersion was concentrated on the 
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pyridine ring, while in the LUMO, it totally shifted to the phenyl ring. This rapid shifting of electronic 
cloud indicates the more reactive nature of compound 4g towards electrophiles when compared to 
the other compounds of this series 4a–4i. 
Table 1. The values of HOMO and LUMO energies for compounds 2a–2i and 4a–4i along with the 
energy gaps (ΔE). All energy values are reported in eV unit. 
Compound HOMO LUMO ΔE 
2a −5.51 −0.67 4.84 
2b −5.51 −0.65 4.86 
2c −5.38 −0.53 4.85 
2d −6.03 −1.40 4.63 
2e −5.72 −0.98 4.74 
2f −5.39 −0.74 4.65 
2g −5.66 −1.52 4.14 
2h −5.80 −1.09 4.71 
2i −5.66 −1.52 4.14 
4a −6.08 −1.07 5.01 
4b −6.10 −1.05 5.05 
4c −5.82 −0.95 4.87 
4d −6.30 −1.37 4.93 
4e −6.42 −1.47 4.95 
4f −5.71 −1.13 4.58 
4g −6.28 −1.75 4.53 
4h −6.55 −1.76 4.79 
4i −6.38 −1.39 4.99 
2.2.2. Reactivity Indices 
Reactivity indices like chemical hardness (η), electrophilicity (ω) and electronic chemical potential 
are excellent tools to describe the chemical hardness, reactivity and stability of compounds [33]. Chemical 
hardness of any compound can be expressed in terms of the following mathematical equation: 
η = (EHOMO − ELUMO)/2  
Using the equation above the chemical hardness of all derivatives 2a–2i and 4a–4i was calculated 
and given in Table 2, along with reactivity indices (electrophilicity and electronic chemical potential). 
From Table 2 it is clear that among all derivatives, 4b has highest value of η i.e., of 2.52 eV and is the 
chemically hardest compound among all, whereas 2g has the lowest value and is chemically soft and 
more reactive. These findings are consistent with the HOMO-LUMO band gaps of all synthesized 
derivatives. The electronic chemical potential (µ) value gives an idea about the charge transfer within 
any compound in its ground state. Mathematically it can be defined by the equation below: 
µ = (EHOMO + ELUMO)/2  
From Table 2, it is clear that 4h has the highest electronic chemical potential value (4.15 eV), 
among both series 2a–2i and 4a–4i while 2c has the lowest chemical potential value.  
The electrophilicity index (ω) is a thermodynamic property that measures the changes in energy 
when a chemical system becomes saturated by adding electrons. It plays an excellent role in describing 
the chemical reactivity of a system and is mathematically defined by the following equation: 
ω = µ2/2η  
where µ is the electronic chemical potential, η is chemical hardness. The results from Table 2 indicate 
that 2b has the lowest electrophilicity index value and is nucleophilic in nature, whereas 4h has the 
highest value i.e., of 3.60 eV and is strongly electrophilic in nature. 
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Table 2. Reactivity indices of compounds 2a–2i and 4a–4i. 
Compound η (eV) µ (eV) ω (eV)
2a 2.42 3.09 1.97 
2b 2.43 3.08 1.95 
2c 2.42 2.95 1.79 
2d 2.31 3.71 2.97 
2e 2.37 3.35 2.36 
2f 2.32 3.06 2.01 
2g 2.07 3.59 3.11 
2h 2.35 3.44 2.51 
2i 2.07 3.59 3.11 
4a 2.5 3.57 2.54 
4b 2.52 3.57 2.52
4c 2.43 3.38 2.35 
4d 2.46 3.83 2.98 
4e 2.47 3.94 3.14 
4f 2.29 3.42 2.55 
4g 2.26 4.01 3.55 
4h 2.39 4.15 3.6 
4i 2.49 3.88 3.02 
2.2.3. Molecular Electrostatic Potential (MEP) Analysis 
MEP analysis with the help of quantum mechanical methods has been used extensively to explain 
the reactive sites within a compound [34]. With MEP analysis, the reactive sites can be located by 
different color codes, such as the red color in a MEP graphic indicates an electron-rich site, blue color 
indicates an electron-deficient site, while the green color is indicative of a neutral region [32]. The MEP 
analysis of both series of compounds viz. 2a–2i and 4a–4i was carried out using the B3LYP/6-31G(d,p) 
basis set of DFT. Figure 2 displays the MEP surfaces of the newly synthesized pyridine derivatives 
viz. 2a–2i, 3, 4a–4i at B3LYP/6-31G(d,p) level of DFT and graphics, while the corresponding +ݒ݁ and 
– ݒ݁ potential values from the MEP analysis of these compounds are given in Table 3. The MEP 
surfaces of compounds 2a–2i exhibited similar electronic density trends. In all these compounds, the 
red color appeared on the pyridine ring nitrogen indicating the electron rich site, while the blue color 
was concentrated on the amino group, reflecting the electron deficient site. 
  
2a 2b 2c 
   
2d 2e 2f 
Figure 2. Cont. 
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2g 2h 2i 
  
4a 4b 4c 
  
4d 4e 4f 
  
4g 4h 4i 
Figure 2. MEP surfaces of the newly synthesized pyridine derivatives viz. 2a–2i, 3, 4a–4i at B3LYP/ 
6-31G(d,p) level of DFT 
Table 3. The +ݒ݁ and – ݒ݁ potential values from the MEP analysis of compounds 2a–2i and 4a–4i. 
Compound +࢜ࢋ Potential −࢜ࢋ Potential
2a −0.05351 0.05351 
2b −0.05365 0.05365 
2c −0.05348 0.05348 
2d −0.05401 0.05401 
2e −0.05124 0.05124 
2f −0.05285 0.05285 
2g −0.05037 0.05037 
2h −0.05193 0.05193 
2i −0.05198 0.05198 
4a −0.05573 0.05573 
4b −0.05579 0.05579 
4c −0.05643 0.05643 
4d −0.05268 0.05268 
4e −0.05207 0.05207 
4f −0.05527 0.05527 
4g −0.05600 0.05600 
4h −0.05275 0.05275 
4i −0.05230 0.05230 
From the MEP analysis, it is clear that the lone pair of the nitrogen in the pyridine ring was 
available for electrophiles. In contrast, the lone pair of the amino group exhibited delocalization on the 
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biphenyl skeleton. Similarly, in the case of the second series of compounds 4a–4i, where a hydrogen 
atom of the amino group was replaced by an acetyl group, the electronic density showed a clear shift 
toward the acetyl group oxygen, as reflected by red color. The light red color on the nitrogen atom of 
pyridine still showed its affinity for electrophiles. 
2.2.4. Dipole Moment 
Biphenyl compounds having restricted rotation around single bonds and a large dipole moment 
exhibit the potential to influence the liquid crystalline properties, therefore, they are frequently used 
as chiral dopants for liquid crystals [35]. Biphenyl compounds having greater dipole moments can 
effectively act as chiral dopants for liquid crystals [36]. The dipole moment of all newly synthesized 
biphenyl derivatives was calculated at the B3LYP/6-31G(d,p) level of theory and are given in Table 4. 
Table 4. The values of dipole moment (Debye) for the newly synthesized pyridine derivatives viz.  
2a–2i, 3, 4a–4i calculated at B3LYP/6-31G(d,p) level of DFT. 
Compounds Dipole moment (Debye)
2a 3.0645 
2b 3.0012 
2c 2.6799 
2d 3.7669 
2e 3.6042 
2f 3.9239 
2g 2.7658 
2h 3.7223 
2i 3.6598 
4a 3.3070 
4b 3.3294 
4c 4.1817 
4d 1.0557 
4e 1.1464 
4f 3.5552 
4g 4.7299 
4h 1.4438 
4i 2.0915 
The dipole moment values for compounds 2a–2i were in the ~2.7658–3.9239 Debye range. 
Compound 2d displayed the highest dipole moment ~3.7669 Debye, indicating a high suitability of 
this compound to act as a chiral dopant for liquid crystals. For the second series of compounds 4a–4i, the 
dipole moment values were recorded in the 1.0557–4.7299 Debye range. Among these compounds, 
compound 4g displayed the highest value of dipole moment, indicating its high suitability in terms 
of chiral dopant properties. 
2.3. Pharmaceutical Studies 
2.3.1. Anti-Thrombolytic Activity 
It has been reported that the thrombotic component is one of the major causes of sudden 
coronary death and myocardial infarction [37,38]. Hence, we have explored the anti-thrombolytic 
activity of all newly synthesized compounds. Table 5 displays the anti-thrombolytic activity values for 
the newly synthesized pyridine derivatives at a concentration of 50 µM/mL. For comparison, 
streptokinase was used as positive control. The results revealed that compound 2i exhibited the highest 
anti-thrombolytic activity (31.61%) among the 2a–2i pyridine derivatives. This high activity indicated 
that compound 2i might be related to the presence of two different halogen groups (chloro and flouro) 
attached at the 3 and 4 positions of the aryl ring, respectively. On the other hand, the compound 2e 
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showed the lowest activity (2.82%), which could be due to the presence of only one halogen moiety 
(chloro) at the 4 position of the aryl ring. Furthermore, other derivatives among the 2a–2i series 
displayed low to moderate anti-thrombolytic activity values, while compound 2g exhibited no 
significant activity against clot formation (Figure 3). 
Table 5. Anti-thrombolytic assay of compounds 2a–2i, 3 and 4a–4i at a concentration of 50 µM/mL. 
Compounds % Lysis
2a 15.2 ± 0.05 
2b 6.43 ± 0.06 
2c 15.4 ± 0.19 
2d 21.3 ± 0.21 
2e 2.82 ± 0.33 
2f 3.72 ± 0.03 
2g 0.43 ± 0.22 
2h 9.04 ± 0.31 
2i 31.6 ± 0.86 
3 34.8 ± 0.03 
4a 21.5 ± 0.04 
4b 41.3 ± 0.43 
4c 2.69 ± 0.16 
4d 13.6 ± 0.09 
4e 6.43 ± 0.21 
4f 12.6 ± 0.15 
4g 29.2 ± 0.03 
4h 6.31 ± 0.41 
4i 14.3 ± 0.03 
Streptokinase 87.45 
 
Figure 3. Anti-thrombolytic, biofilm inhibition and haemolytic activities of compounds 2a–2i, 3. 
Among the derivatives 4a–4i, compound 4b exhibited the highest activity (41.32%) against clot 
formation in human blood (Table 5, Figure 4). This high activity displayed by 4b compared to its 
analogue 2b, might have its origin in the acyl group attached on the amino group in 4b. Compound 4c 
exhibited the lowest activity against clot formation in human blood among all newly synthesized pyridine 
derivatives 4a–4i. The results in Table 5 reveal that compounds 4g and 4a displayed moderate activity 
values viz. 29.21% and 21.51%, respectively. Overall, it can be seen that the type of substituents and their 
0
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position on the aryl group had a significant influence on the anti-thrombolytic activity of the newly 
synthesized compounds. On the basis of these anti-thrombolytic activity results (Table 5), it is suggested 
that the pyridine derivatives containing amino groups masked with an acyl group, and substituted 
aryl rings displayed moderate to good characteristics to inhibit the formation of clots in human blood. 
2.3.2. Biofilm Inhibition Activity 
Bacterial biofilms are formed when unicellular organisms form a community that adheres itself to 
a solid surface and is encased in an exopolysaccharide matrix [39]. It is generally accepted that biofilms 
can limit the effect of medicine to a great extent [40–42]. Hence, the anti-biofilm activity of all newly 
synthesized pyridine-based compounds was evaluated against strains of Escherichia coli. Rifampicin 
was used as standard positive control. The corresponding values of anti-biofilm activity measured for 
all compounds at a concentration of 50 µM/mL are given in Table 6. In comparison with standard drug 
rifampicin (97.53%), compound 2f exhibited the highest activity (90.95 %) among derivatives 2a–2i. This 
activity displayed by the compound 2f can be attributed to the existence of the bulky –SMe group 
attached to the phenyl ring of this compound. Some of the other compounds such as 2g, 2d, 2a, 2c and 
2e also exhibited good anti-bacterial activities (83.76%, 82.04%, 80.05%, 79.78%, 79.38%, respectively) 
against E. coli. Among all 2a–2i compounds, compound 2i exhibited the lowest inhibition (69.54%) 
compared to the positive control rifampicin (Figure 3).  
Table 6. Biofilm inhibition assay of the compounds (2a–2i, 3 and 4a–4i) at a concentration of 50 µM/mL. 
Compounds % Inhibition
2a 80.05 ± 0.001 
2b 77.39 ± 0.040 
2c 79.78 ± 0.007 
2d 82.04 ± 0.360 
2e 79.38 ± 0.030 
2f 90.95 ± 0.023 
2g 83.76 ± 0.051 
2h 78.98 ± 0.212 
2i 69.54 ± 0.291 
3 89.63 ± 0.213 
4a 87.36 ± 0.031 
4b 83.90 ± 0.112 
4c 82.97 ± 0.023 
4d 84.30 ± 0.121 
4e 87.09 ± 0.321 
4f 91.95 ± 0.291 
4g 83.62 ± 0.521 
4h 82.52 ± 0.02 
4i 86.48 ± 0.032 
Rifampicin 97.53 ± 0.021 
In the case of pyridine derivatives 4a–4i, the results in Table 6 show that compound 4f exhibited 
the highest anti-bacterial activity (91.95%) compared to all other compounds from this series (Figure 4). 
Since the anti-bacterial activity of these compounds differ with the functional groups, the superior 
activity exhibited by the compound 4f could be due to the presence of the thiomethyl group on the 
phenyl ring in this compound. Several other compounds from this series such as compounds 4a, 4e, 4i, 
4d, 4b, 4g, 4c also exhibited fairly high anti-bacterial activity, evidenced by bio-film inhibition against 
strains of E. coli with values ~87.36%, 87.09%, 86.48%, 84.30%, 83.90%, 83.62 and 82.97%, respectively. 
The lowest bio-film inhibition value was displayed by compound 4h and it is plausible that the attached 
iodo substituent might be the possible cause of this low anti-bacterial activity. Overall, the results for 
anti-bacterial activity measurements reveal that most of the compounds from both pyridine derivative 
series 2a–2i and 4a–4i exhibit moderate to good biofilm inhibition values against E. coli. In general, it 
is quite evident that the electron-donating and electron-withdrawing groups attached to different sites 
Molecules 2017, 22, 190 11 of 19 
 
of the phenyl ring are responsible for the different antibacterial activity against E. coli. The pyridine 
derivatives 4a–4i exhibited relatively better anti-bacterial activities compared to the 2a–2i series of 
compounds. Moreover, one approach to enhance the anti-bacterial activity is to mask the amino functional 
group with an acyl group, as seen earlier in the case of compound 4b. Hence, pyridine derivatives 
containing an amino group masked by an acyl group produce potentially useful compounds that can 
successfully inhibit the formation of biofilms formed by E. coli. 
2.3.3. Haemolytic Activity 
The haemolytic activity of the newly synthesized pyridine derivatives 2a–2i and 4a–4i and 
compound 3 was also examined. For comparison purposes Triton X-100 was employed as the positive 
control. The cytotoxicity values for these novel derivatives at a concentration of 50 µM/mL are 
expressed in Table 7. Among derivatives 2a–2i, compound 2i exhibited the highest percentage lysis 
(11.72%) against red blood cells (RBCs). This superior haemolytic activity displayed by compound 2i 
might be related with the halogen functional groups (–Cl and –F) attached to the aryl ring in this 
compound. In contrast, the compound 2g exhibited the lowest cytotoxicity (2.52%) against RBCs, possibly 
due to the presence of acyl group attached to the aromatic ring which somehow inhibits the activity of 
this compound against red blood cells. 
In the case of pyridine 4a–4i derivatives, compound 4g displayed the highest cytotoxicity (19.82%) 
when compared with the standard drug. Given the presence of two acyl groups in this compound, this 
remarkably high cytotoxic activity displayed by the compound 4g was somewhat surprising. From this 
result, it can be established that upon masking the amino group with an acyl group in the pyridine 
derivatives, high cytotoxic activity can be achieved against RBCs. The results from Table 7 revealed that 
the compound 4e also exhibited good percentage lysis (8.28%) against RBCs. Other pyridine molecules 
exhibited low to moderate haemolytic activity when compared to Triton X-100. Overall, the results 
reveal that the haemolytic activity of the newly synthesized pyridine derivatives showed significant 
variations due to the presence of different substituents at the aromatic ring in these compounds. The 
high haemolytic activity displayed by most of the newly synthesized pyridine derivatives make them 
potential active anti-tumor agent candidates [43]. 
Table 7. Heamolytic assay of the compounds (2a–2i, 3 and 4a–4i) at a concentration of 50 µM/mL. 
Compounds % Lysis
2a 5.45 ± 0.02 
2b 3.21 ± 0.51 
2c 5.40 ± 0.09 
2d 7.87 ± 0.21 
2e 5.92 ± 0.05 
2f 4.82 ± 0.03 
2g 2.52 ± 0.03 
2h 4.94 ± 0.11 
2i 11.7 ± 0.17 
3 13.6 ± 0.57 
4a 2.32 ± 0.04 
4b 4.82 ± 0.04 
4c 3.67 ± 0.06 
4d 3.39 ± 0.29 
4e ±8.28 0.14
4f 6.55 ± 0.03 
4g 19.82 ± 0.37 
4h 3.39 ± 0.04 
4i 4.48 ± 0.03 
Triton X-100 99
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Figure 4. Anti-thrombolytic, biofilm inhibition and haemolytic activities of compounds (4a–4i). 
3. Experimental Section 
3.1. General Information 
A Buchi B-540 melting point apparatus (Buchi, New Castle, DE, USA) was used to measure the 
melting points of the newly synthesized pyridine derivatives. For qualitative analysis, an AM-400 NMR 
spectrometer (Bruker, Billercia, MA, USA) was applied and the 13C-NMR and 1H-NMR spectra were 
obtained in CDCl3 and CD3OD at 400/100 MHz, respectively. All chemicals used in the present work 
were acquired from Sigma Aldrich (St. Louis, MO, USA) and Alfa Aesar (Ward Hill, MA, USA). EIMS 
spectra were obtained on a JMS-HX-110 spectrometer (JEOL, Peabody, MA, USA).  
3.2. General Procedure for the Synthesis of Compounds 2a–2i 
All compounds were synthesized following the previously reported method [28]. Briefly 5-
bromo-2-methylpyridin-3-amine (1, 0.2 g with tetrakis(triphenylphosphine)palladium (5 mol %) and 
1,4-dioxane (2 mL) were mixed in a Schlenk flask. The reaction mixture was stirred at room temperature 
for 30 min and then the arylboronic acid (1.1759 mmol), potassium phosphate (2.318 mmol) and water 
(0.5 mL) were added and the mixture again stirred at 85–95 °C for more than 15 h. After lowering the 
temperature, the mixture was filtered and diluted with ethyl acetate (50 mL). The excess solvent in the 
solution was evaporated by rotary evaporator in order to obtain a concentrated solution. Column 
chromatography was applied to get the desired pure product (silica gel, n-hexane and ethyl acetate). The 
final products were dried, recrystallized and then characterized using different spectroscopic techniques. 
2-Methyl-5(4-methylphenyl)pyridin-3-amine (2a). m.p.: 208–209 °C. 1H-NMR (CDCl3) δ 7.99–7.64 (m, 2H-
pyridine), 7.41 (m, 2H-Ar), 7.21 (m, 2H-Ar), 2.50 (s, 3H-methyl), 2.41 (s, 3H-methyl); 13C-NMR (CDCl3 
+ CD3OD) δ 16.7, 21.3, 120.5, 126.8, 128.8, 132.5, 133.8, 134.9, 144.2, 145.8. EI-MS m/z (+ion mode): 198, 
[M − NH2]+ = 183, [M − NH2 and CH3]+ = 170, [M − NH2 and 2CH3]+ = 155. Anal. calcd for C13H14N2 
(198.26): C, 78.74; H, 7.11. Found: C, 78.69; H, 7.02%. 
5-(3,5-Dimethylphenyl)-2-methylpyridin-3-amine (2b). m.p.: 232–233 °C. 1H-NMR (CDCl3) δ 8.2 (s, 1H-
pyridine), 7.6 (m, 2H-Ar), 7.3–7.02 (m, 1H-pyridine, 1H-Ar), 2.51 (s, 3H-methyl), 2.41 (s, 3H-methyl); 
13C-NMR (CDCl3 + CD3OD) δ 15.5, 21.5, 120.5, 125.3, 130.6, 132.0, 134.1, 136.4, 138.3, 144.3, 145.8.  
EI-MS m/z (+ion mode): 212, [M − NH2]+ = 197, [M − NH2 and CH3]+ = 183, [M − NH2 and 3CH3]+ = 140. 
Anal. calcd for C14H16N2 (212.25): C, 79.19; H, 7.59. Found: C, 78.17; H, 7.56%. 
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5-(4-Methoxyphenyl)-2-methylpyridin-3-amine (2c). m.p.: 232 °C. 1H-NMR (CDCl3) δ 8.12 (s, 1H-pyridine), 
7.55 (m, 2H-Ar), 7.31 (m, 1H-pyridine), 7.03 (m, 2H-Ar), 3.9 (s, 3H-methyl), 2.45 (s, 3H-methyl); 13C-NMR 
(CDCl3 + CD3OD) δ 17.1, 55.6, 114.7, 120.5, 128.4, 129.8, 132.3, 134.3, 144.3, 145.8, 160.3. EI-MS m/z (+ion 
mode): 214, [M − NH2]+ = 199, [M − NH2 and CH3]+ = 185, [M − OCH3]+ = 184. Anal. calcd for C13H14N2O 
(214.21): C, 72.79; H, 6.55. Found: C, 72.75; H, 6.53%. 
5-(4-Iodophenyl)-2-methylpyridin-3-amine (2d). m.p.: 258 °C. 1H-NMR (CDCl3) δ 8.09 (s, 1H-pyridine), 
7.71–7.49 (m, 4H-Ar), 7.15 (s, 1H-pyridine), 2.5 (s, 3H-methyl); 13C-NMR (CDCl3 + CD3OD) δ 15.8, 94.1, 
120.1, 130, 132.1, 134.5, 135.7, 138.4, 144.2, 145.5. EI-MS m/z (+ion mode): 310, [M − NH2]+ = 295, [M − NH2 
and CH3]+ = 281, [M − I]+ = 184. Anal. calcd for C12H11IN2 (310.13): C, 46.47; H, 3.58. Found: C, 46.41; 
H, 3.52%. 
5-(4-Chlorophenyl)-2-methylpyridin-3-amine (2e). m.p.: 228 °C. 1H-NMR (CDCl3) δ 8.2 (s, 1H-pyridine), 
7.71–7.41 (m, 4H-Ar), 7.11 (s, 1H-pyridine), 2.5 (s, 3H, methyl); 13C-NMR (CDCl3 + CD3OD) δ 15.7, 120.4, 
128.3, 129.8, 132, 134.3, 135.3, 144.2, 145.6. EI-MS m/z (+ion mode): 310, [M − NH2]+ = 295, [M − NH2 
and CH3]+ = 281, [M − I]+ = 184. Anal. calcd for C12H11ClN2 (218.68): C, 66.01; H, 5.07. Found: C, 66.0; 
H, 5.03%. 
2-Methyl-5-[4-(methylsulfonyl)phenyl]pyridin-3-amine (2f). m.p.: 240 °C. 1H-NMR (CDCl3) δ 8.23 (s, 1H-
pyridine), 7.69–7.11 (m, 4H-Ar, 1H-pyridine), 2.59 (s, 3H, methyl), 2.5 (s, 3H, methyl). 13C-NMR 
(CDCl3 + CD3OD) δ 14.6, 17, 120.1, 127.2, 128.3, 132.2, 133.4, 135, 139.5, 144, 146.1. EI-MS m/z (+ion 
mode): 230, [M − NH2]+ = 215, [M − NH2 and CH3]+ = 201, [M − SCH3]+ = 184. Anal. calcd for C13H14N2S 
(230.33): C, 66.98; H, 5.99. Found: C, 66.95; H, 5.95%. 
1-[3-(5-Amino-6-methylpyridin-3-yl)phenyl]ethanone (2g). m.p.: 270 °C. 1H-NMR (CDCl3) δ 8.24 (d, J = 
3.4 Hz, 1H-Ar), 8.17 (s, 1H-pyridine), 7.96–7.49 (m, 3H-Ar), 7.25 (s, 1H-pyridine), 2.7 (s, 3H-COCH3), 
2.5 (s, 3H-methyl). 13C-NMR (CDCl3 + CD3OD) δ 16.3, 26.4, 120.5, 126.5, 128.2, 129.7.131.2, 132.8, 134.8, 
136.6, 138, 144.5, 146.1, 195. EI-MS m/z (+ion mode): 226 [M + H]+: [M − NH2]+ = 211: [M − NH2 and 
CH3]+ = 197: [M − OCH3]+ = 184. Anal. calcd for C14H14N2O (226.19): C, 74.27; H, 6.18. Found: C, 74.26; 
H, 6.17%. 
5-(3,5-Difluorophenyl)-2-methylpyridin-3-amine (2h). m.p.: 208 °C. 1H-NMR (CDCl3) δ 7.9 (s, 1H-pyridine), 
7.57 (m, 1H-pyridine), 7.55–6.82 (m, 3H-Ar), 2.5 (s, 3H, methyl). 13C-NMR (CDCl3 + CD3OD) δ 16.3, 
104.8, 111.2, 120, 132.4, 134.5, 139.3, 144.3, 145.8. EI-MS m/z (+ion mode): 220 [M + H]+: [M − NH2]+ = 
205: [M − NH2 and CH3]+ = 191: [M − 2F]+ = 184. Anal. calcd for C12H10F2N2 (220.22): C, 65.45; H, 4.56. 
Found: C, 65.41; H, 4.54%. 
5-(3-Chloro-4-fluorophenyl)-2-methylpyridin-3-amine (2i). m.p.: 240 °C. 1H-NMR (CDCl3) δ 8.22 (s, 1H-
pyridine), 7.72–7.08 (m, 3H-Ar, 1H-pyridine), 2.5 (s, 3H, methyl). 13C-NMR (CDCl3 + CD3OD) δ 16.6, 
117.1, 120.4, 121.1, 128, 129.4, 132.2, 133.1, 134.6, 143.9, 145.2. EI-MS m/z (+ion mode): 236 [M + H]+:  
[M − NH2]+ = 221: [M − NH2 and CH3]+ = 207: [M − F]+ = 218: [M − Cl]+ = 202: [M − F and Cl]+ = 184. 
Anal. calcd for C12H10ClFN2 (236.67): C, 60.90; H, 4.27. Found: C, 60.85; H, 4.22%. 
3.3. Synthesis of N-[5-Bromo-2-methylpyridine-3-yl]acetamide (3) 
Under a nitrogen atmosphere, a solution of 5-bromo-2-methylpyridine-3-amine (1, 2 g), acetic 
anhydride (1.95 g) and acetonitrile (20 mL) was stirred at 60 °C and treated with 96% H2SO4 (a few 
drops). Stirring was continued for another half an hour while the reaction was monitored by TLC. 
The reaction mixture was evaporated and allowed to cool to room temperature. After cooling, water 
was added dropwise to form a precipitate. Then the mixture was stirred near one hour around room 
temperature and then filtered. The impure solid was washed with deionized water and later dried in 
an oven [44]. 
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N-[5-Bromo-2-methylpyridine-3-yl]acetamide (3). Yield: 85 %; m.p.: 256 °C. 1H-NMR (CDCl3) δ 7.8 (s, 1H-
pyridine), 7.38 (s, 1H-pyridine), 2.6 (s, 3H, methyl), 2.45 (s, 3H, COCH3). 13C-NMR (CDCl3 + CD3OD) δ 
16.5, 24.1, 112.3, 127.9, 147.2, 150, 169.1. EI-MS m/z (+ion mode): 229 [M + H]+: [M − CH3]+ = 207: [M − 
Br]+ = 150. Anal. calcd for C8H9BrN2O (229.07): C, 41.95; H, 4.01. Found: C, 41.93; H, 3.97%. 
3.4. General Procedure for the Synthesis of Compounds 4a–4i 
All compounds were synthesized by reported method [28]. N-[5-bromo-2-methylpyridine-3-
yl]acetamide (3, 0.1 g), tetrakis(triphenylphosphine)-palladium (5 mol %) and 1,4-dioxane (2 mL) were 
placed in the Schlenk flask at room temperature and the mixture was stirred for 30 min . Then the 
appropriate arylboronic acid (1.1 mmol), potassium phosphate (1.5 mmol) and H2O (0.5 mL) were added 
to the mixture, which was stirred and kept at 85–95 °C for more than 15 h. After reaching room 
temperature, the mixture was filtered and then diluted with ethyl acetate (50 mL). The excess solvent was 
evaporated by rotary evaporator in order to obtain a concentrated solution. Column chromatography 
(silica gel, n-hexane and ethyl acetate?) was applied to obtain the desired pure products. The final 
product was dried and recrystallized and further analyzed using different spectroscopic techniques. 
5-(3-Chloro-4-fluorophenyl)-2-methylpyridin-3-amine (4a). m.p.: 310 °C. 1H-NMR (CDCl3) δ 8.77 (s, 1H-
pyridine), 8.7 (d, J =2.5 Hz, 1H-pyridine), 7.6 (m, 2H-Ar), 7.4 (m, 2H-Ar), 2.65 (s, 3H, methyl), 2.5 (s, 
3H, methyl), 2.4 (s, 3H, COCH3). 13C-NMR (CDCl3 + CD3OD) δ 16.4, 21.5, 24.2, 126.1, 127.6, 129.2, 132.1, 
133.2, 134, 136.8, 149.2, 168.2. EI-MS m/z (+ion mode): 240 [M + H]+: [M − CH3]+ = 226: [M − 2CH3]+ = 
212. Anal. calcd for C15H16N2O (240.3): C, 74.89; H, 6.69. Found: C, 74.87; H, 6.65%. 
N-[5-(3,5-Dimethylphenyl)-2-methylpyridine-3-yl]acetamide (4b). m.p.: 338 °C. 1H-NMR (CDCl3) δ 8.6 (s, 
1H-pyridine), 8.5 (s, 1H-pyridine), 7.49 (d, 2H-Ar), 7.35 (s, 1H-Ar), 2.49 (s, 3H, methyl), 2.32 (s, 6H, 
methyl), 2.05 (s, 3H, COCH3). 13C-NMR (CDCl3 + CD3OD) δ 16.5, 21.7, 24, 125.2, 126.6, 130.1, 133.5, 136.4, 
138.6, 149.3, 167.9. EI-MS m/z (+ion mode): 254 [M + H]+: [M − CH3]+ = 240: [M − 3CH3]+ = 212. Anal. calcd 
for C16H18N2O (254.33): C, 75.48; H, 7.09. Found: C, 75.45; H, 7.07%. 
N-[5-(4-Methoxyphenyl)-2-methylpyridine-3-yl]acetamide (4c). m.p.: 337 °C. 1H-NMR (CDCl3) δ 8.27 (s, 1H-
pyridine), 7.7 (d, J = 2.3 Hz, 1H-pyridine), 7.15–7.05 (m, 4H-Ar), 3.95 (s, 3H, methoxy), 2.6 (s, 3H, methyl), 
1.75 (s, 3H, COCH3). 13C-NMR (CDCl3 + CD3OD) δ 16.6, 24, 55.6, 114.7, 126.2, 128.3, 129.9, 133.3, 136.8, 
149.4, 160.5, 168.3. EI-MS m/z (+ion mode): 256 [M + H]+: [M − CH3]+ = 242: [M − 2CH3]+ = 228. Anal. 
calcd for C15H16N2O2 (256.30): C, 70.29; H, 6.26. Found: C, 70.27; H, 6.24%. 
N-[5-(4-Chlorophenyl)-2-methylpyridine-3-yl]acetamide (4d). m.p.: 316 °C. 1H-NMR (CDCl3) δ 8.48 (s, 1H-
pyridine), 8.22 (s, 1H-pyridine), 7.55 (m, 2H-Ar), 7.45 (m, 2H-Ar), 2.5 (s, 3H, methyl), 2.22 (s, 3H, methyl). 
13C-NMR (CDCl3 + CD3OD) δ 16.1, 24.2, 126.6, 128.7, 129.9, 133.4, 134.7, 136.5, 149.2, 169.1. EI-MS m/z 
(+ion mode): 260 [M + H]+: [M − CH3]+ = 247: [M − Cl]+ = 226: [M − Cl and CH3]+ = 212. Anal. calcd for 
C14H13ClN2O (260.72): C, 64.49; H, 5.08. Found: C, 64.44; H, 5.02%. 
N-[5-(3,5-Difluorophenyl)-2-methylpyridine-3-yl]acetamide (4e). m.p.: 310 °C. 1H-NMR (CDCl3) δ 8.73 (s, 
1H-pyridine), 8.46 (s, 1H-pyridine) 7.29 (m, 2H-Ar), 6.64 (s, 1H-Ar), 2.53 (s, 3H-methyl), 2.04 (s,  
3H-methyl). 13C-NMR (CDCl3 + CD3OD) δ 16.6, 24.3, 104.9, 111.2, 126.7, 133.8, 136.5, 139.3, 149.5, 164.8, 
168.4. EI-MS m/z (+ion mode): 262 [M + H]+: [M − CH3]+ = 248: [M − 2F]+ = 226. Anal. calcd for 
C14H12F2N2O (262.23): C, 64.12; H, 4.61. Found: C, 64.08; H, 4.54%. 
N-[2-Methy-5-(4-methylsulfonyl)phenylpyridin-3-yl]acetamide (4f). m.p.: 325 °C. 1H-NMR (CDCl3) δ 7.69–7.39 
(m, 4H-Ar, 2H-pyridine), 2.55 (s, 3H-methyl), 1.7 (s, 3H-methyl). 13C-NMR (CDCl3 + CD3OD) δ 14.7, 16.8, 
24.2, 127.1, 128.2, 132.8, 133.8, 136.2, 139.1, 149.6, 168.5. EI-MS m/z (+ion mode): 272 [M + H]+: [M − CH3]+ 
= 258: [M − 2CH3]+ = 244. Anal. calcd for C15H16N2OS (272.37): C, 66.15; H, 5.92. Found: C, 66.10; H, 5.91%. 
N-[5-(3-Acetylphenyl)-2-methylpyridine-3-yl]acetamide (4g). m.p.: 340 °C. 1H-NMR (CDCl3) δ 8.33 (s,  
1H-pyridine), 8.25 (d, J = 1.9 Hz, 1H-pyridine), 8.0 (m, 1H-Ar), 7.80 (m, 1H-Ar), 7.68 (m, 1H-Ar), 7.4 (m, 
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1H-Ar), 2.71 (s, 3H, methyl), 2.51 (s, 3H, COCH3), 2.09 (s, 3H, methyl). 13C-NMR (CDCl3 + CD3OD) δ 
16.5, 24.6, 26.3, 125.8, 126.9, 127.7, 128.6, 129.5, 132, 133.7, 136.2, 137.3, 148.6, 167.8, 196.6. EI-MS m/z 
(+ion mode): 268 [M + H]+: [M − CH3]+ = 254: [M − OCH3]+ = 226. Anal. calcd for C16H16N2O2 (268.29): 
C, 71.59; H, 5.99. Found: C, 71.55; H, 5.96%. 
N-[5-(4-iodophenyl)-2-methylpyridine-3-yl]acetamide (4h). m.p.: 333 °C. 1H-NMR (CDCl3) δ 8.73 (s, 1H-
pyridine), 8.46 (d, J = 2.5 Hz, 1H-pyridine), 7.99 (m, 2H-Ar), 7.56 (m, 2H-Ar), 2.53 (s, 3H, methyl), 2.04 
(s, 3H, COCH3). 13C-NMR (CDCl3 + CD3OD) δ 16.7, 23.9, 94.5, 126.3, 128.2, 130.5, 133.6, 135.7, 136.9, 
138.4, 149.1, 168.8. EI-MS m/z (+ion mode): 352 [M + H]+: [M − CH3]+ = 338: [M − F]+ = 226: [M − F and 
CH3]+ = 212. Anal. calcd for C14H13IN2O (352.17): C, 47.75; H, 3.72. Found: C, 47.71; H, 3.67%. 
N-[5-(3-chloro-4-fluorophenyl)-2-methylpyridine-3-yl]acetamide (4i). m.p.: 325 °C. 1H-NMR (CDCl3) δ 8.2 
(s, 1H-pyridine) 7.71 (m, 1H-pyridine), 7.5 (m, 1H-Ar), 7.35 (d, J = 8.2 Hz, 1H-Ar), 7.09 (d, J = 8.1, 1H-Ar), 
2.45 (s, 3H, methyl), 1.7 (s, 3H, COCH3). 13C-NMR (CDCl3 + CD3OD) δ 15.9, 24.4, 117.8, 126.3, 127.9, 129.5, 
132.9, 135.5, 136.9, 150, 158.1, 167.5. EI-MS m/z (+ion mode): 279 [M + H]+: [M − CH3]+ = 265: [M − F]+ = 
261: [M − Cl]+ = 244: [M − Cl and F]+ = 226. Anal. calcd for C14H12ClFN2O (278.71): C, 60.33; H, 4.34. 
Found: C, 60.27; H, 4.29%. 
3.5. Computational Methods 
Density functional theory calculations were executed with the help of the GAUSSIAN 09 software 
[45] and results/graphics were analyzed with the help of Gauss view 05 [46]. Energy minima geometries 
of compounds 2a–2i and 4a–4i were optimized without any symmetry constraints at hybrid B3LYP 
(Becke 3-Parameter, Lee, Yang and Parr) method using 6-31G(d,p) basis set. Frequency analysis was 
performed at the same level of theory, in order to confirm true optimization. Frontier molecular 
orbitals (FMOs) analysis, molecular electrostatic potential (MEP) analysis and dipole measurements 
were executed by using the B3LYP/6-31G(d,p) basis set and at DFT level of theory. 
3.6. Anti-Thrombolytic Assay 
The anti-thrombolytic activity of the novel pyridine derivatives was determined by applying a 
previously reported method [26]. Human blood was taken from volunteers and kept in sterile 
microcentrifuge tubes. The clot formation in blood was done, when microcentrifuge tubes having  
500 μL blood were incubated for the time of 45 min at optimum temperature (37 °C). After clot 
formation, the serum was separated and 100 µL test sample solution from the compound (2a–2i, 3, 
4a–4i) at a concentration of 50 µM/mL were transferred in microcentrifuge tubes. After adding the 
samples, the tubes were incubated again for the duration of more than 90 min at 37 °C. To act as a 
positive control, streptokinase was used in this assay, while water was used as a negative control. 
The final results, shown by test samples against clot formation, were measured in percentage. This 
study was approved by the Board of studies Department of Chemistry and Director advanced 
studies, Govt. College University, Faisalabad (DAS600). 
3.7. Biofilm Inhibition Assay by Microliter-Plate Method 
The anti-bacterial activity of new pyridine molecules was determined by applying a reported method 
[25]. Test sample solutions (100 µL) from the compounds 2a–2i, 3, 4a–4i at a concentration of 50 µM/mL 
along with bacterial suspension (20 µL) were placed in sterile 96-well plastic tissue culture plates, 
which were later incubated for one day at 37 °C. After incubation, phosphate buffer (220 µL) was 
applied to treat the content of each plate thrice. The plates were shaken vigorously to eliminate non-
adherent bacteria and the remaining bacteria were fixed with methanol solution (220 µL, 99%). After 
drying, the plates were stained by using Crystal Violet solution (220 mL, 50%) for 5 min. Tap water 
was used to remove the excess stain from plates. Glacial acetic acid (220 µL, 33%) was then applied 
in order to resolubilise the dye attached to adherent cells. The OD value was determined for each 
well at 630 nm by a micro-plate reader (BioTek, Winooski, VT, USA). 
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3.8. Haemolytic Assay 
The synthesized molecules were evaluated for their haemolytic activity following a previously 
reported method [47]. In brief, heparinized human blood (3 mL) was taken in sterile Falcon tubes. 
The tubes were centrifuged at 850 rpm for 5 min. The upper blood layer was taken out and the pellet 
was washed three times. With the help of ice cold phosphate buffered saline (PBS, 20 mL), the red blood 
cells were counted via a haemocytometer. The red blood cells were kept on ice and diluted using the 
pure phosphate buffer saline to 7.068 × 108 cells per mL. Next each compound 2a–2i, 3, 4a–4i (20 µL) 
was placed in a 2 mL microfuge tube. Triton X-100 with 100% lysis was used as positive control. For the 
negative control, phosphate buffered saline with 0.07% lysis was used. The contents of the microfuge 
tubes were diluted after adding the suspension of blood cells (180 µL). At a temperature of 37 °C, the 
tubes were incubated for 40 min. After that, the tubes were kept on ice for 5–7 min and then centrifuged 
at 1315 rpm for 6 min. From this incubated tube, 100 µL of the upper layer was separated, diluted by 
using ice cold phosphate buffered saline (900 µL). All the test sample solutions (200 µL) were placed 
into 96-well plates. The absorption of each sample was measured by a µ-Quant instrument at 576 nm. 
This study was approved by the Board of studies Department of Chemistry and Director advanced 
studies, Govt. College University, Faisalabad (DAS600). 
4. Conclusions 
The present study describes the efficient synthesis in moderate to good yield of a series of novel 
pyridine derivatives by the application of palladium catalyzed Suzuki cross-coupling reactions of  
5-bromo-2-methylpyridin-3-amine (1) and N-[5-bromo-2-methylpyridine-3-yl]acetamide (3) with 
several arylboronic acids. Frontier molecular orbitals (FMO) analysis reveals that the spread of 
isodensity was mainly concentrated on the aromatic and pyridine rings. The HOMO/LUMO band 
gap studies for all the newly synthesized systems reveal that compound 2g exhibited the lowest band 
gap (~4.14 eV), while compound 4b displayed the highest band gap (~5.05 eV), indicating that 
compound 2g is the most reactive and 4b the least reactive among all the newly synthesized 
compounds. The chemical hardness of 4b has the highest value (2.52 eV), whereas 2g displayed the 
lowest value, chemically softness and reactivity. Among all derivatives 4h has the highest value of 
electronic chemical potential (4.15 eV). The electrophilicity index described the electrophilicity and 
nucleophilicity quantitatively (2b is more nucleophilic and 4b is more electrophilic). The MEP 
analysis showed that the negative potential was mainly concentrated on the pyridine ring nitrogen 
and the positive potential in the compounds 2a–i was mostly concentrated on the amino group. The 
highest dipole moment value was exhibited by 4g (4.7299 Debye), indicating its strong potential to act 
as a chiral dopant for liquid crystals. Further studies on the biological activities of these compounds 
such as anti-thrombolytic, biofilm inhibition and haemolytic activities revealed the moderate to good 
biological activities of these newly synthesized pyridine derivatives. Compound 4b exhibited the highest 
anti-thrombolytic activity (~41.32%) against clot formation among all the newly synthesized 
compounds. In addition, compound 4f exhibited the highest antibacterial activity (~91.95%) against 
bacterial biofilm formation. In this study, the biological screening results established the effect of 
different functional groups present at the aromatic ring. In summary, the biological activity studies 
suggest the potential use of these novel pyridine derivatives as useful compounds for several applications. 
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/ 
22/2/190/s1. 
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